as 02-14-2025 9:59am EST
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.
Founded: | 2013 | Country: | United Kingdom |
Employees: | N/A | City: | HOLYTOWN |
Market Cap: | 3.3M | IPO Year: | 2022 |
Target Price: | $2.40 | AVG Volume (30 days): | 70.8K |
Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | N/A | EPS Growth: | N/A |
52 Week Low/High: | $2.72 - $654.00 | Next Earning Date: | 11-25-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
TCBP Breaking Stock News: Dive into TCBP Ticker-Specific Updates for Smart Investing
Clinical Trials Arena
5 hours ago
PR Newswire
a day ago
MT Newswires
4 days ago
PR Newswire
4 days ago
MT Newswires
9 days ago
PR Newswire
9 days ago
PR Newswire
a month ago
PR Newswire
a month ago
The information presented on this page, "TCBP TC BioPharm (Holdings) plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.